BackgroundIn 2002, US-FDA launched an initiative, ‘‘Pharmaceutical CGMPs for the 21st Century—A Risk-Based Approach,’’ to enhance and modernize the regulation of pharmaceutical manufacturing and product quality.1 One objective, among others, was to facilitate the implementation of a modern, Risk-based Pharmaceutical Quality Assessment system. The desired state has been described as a maximally efficient, agile, flexible…